Rob_McCutcheon

Psychiatrist & researcher. Interested in networks, neurochemistry, multimodal imaging & psychosis

[Rob_McCutcheon @rob_mccutcheon]

Come and help us understand how to treat psychotic disorders better. New clinical fellow posts available to study muscarinic agonists as a treatment for early psychosis!
https://t.co/XbqdlrhrsW

[Wendy Burn CBE @wendyburn]

@hfp91 @nuwandiss @Megsenmumdr @rcpsych At some point psychiatry got taken over by an ideology that we were “creating dependence” by keeping patients on long term. I tried to fight against it but it was hopeless. The patient voice didn’t exist then, nowadays I would try to use that to make the point.

[Helen Lewis @helenlewis]

Uta Frith, one of the world's leading experts on autism, now believes that we might be thinking about it wrong:

[Alan Carson @AlanCarson15]

Please no more mandatory training - the list is becoming endless. I recognise the importance of eating disorders just as i recognise blood transfusion, fire safety, infants at risk if harm etc etc the solution to gsps in services is no yet more mandatory training

[Rob_McCutcheon @rob_mccutcheon]

🚨 Last week to apply 🚨
2 roles on the Wellcome FOCUS study (Early Psychosis) at Oxford comparing Cobenfy vs standard treatment, with multimodal imaging

🔹 Clinical Fellow (F2/CT)
🔹 Research Assistant

Clinical https://t.co/BXCsAcNMHS
RA:https://t.co/kcvKg7zZ8b

[Rob_McCutcheon @rob_mccutcheon]

🚀 We’re hiring!

Join FOCUS a Wellcome-funded study – as a resident doctor
🧠 Compare a novel non-dopaminergic treatment with standard antipsychotics
🔬 Work with cognition + neuroimaging + ML

📆 12-month post |Potential DPhil/DMPhD Apply: https://t.co/BXCsAcOkxq

[Imperial Department of Brain Sciences @ImperialBrains]

🚨 PhD Opportunity!

A 3 year project on dopaminergic dysregulation in bipolar disorder & psychosis, using neuromelanin-sensitive MRI.

🔬Supervised by @sameerjauhar and @rob_mccutcheon.
📅 Deadline: 5 Sept
💸 £22,780 stipend

Apply now👇
https://t.co/Mf2k8EUVPT

[Sameer Jauhar @sameerjauhar]

Does Mother Nature Read the DSM? Findings from our new paper in @JAMAPsych https://t.co/rws7kPlXPW

[Ash Paul @pash22]

Can administrative real-world data substitute for RCTs and offer propensity matching to reduce bias?
Results often fail to correspond & @LGHemkens et al study showed direction of effect differed in 31% & CI failed to include RCT estimate in 56%
https://t.co/aaQUuW2p6z

[Michael Totty @MicTott]

This should be required reading by all graduate students and postdocs | A brief guide to statistical analysis of grouped data in preclinical research https://t.co/DNW4OXQ1xA

[Callum Williams @cmwilliams99]

Once again, @NHSE_WTE have made a decision without consultation and despite strong opposition from students and academics

We at @BMAstudents & @BMA_Academics have written to NHSE to demand they restart discussions to return SFP to merit-based recruitment.

[Toby Pillinger @tobypill]

It was great to launch our international guidelines for treatment of schizophrenia at the @SIRSGlobal annual congress - many thanks to all those who contributed, especially @rob_mccutcheon

Read here: https://t.co/1u0NoACfRb

Use the digital tool: https://t.co/jfchQvzQwB

[Jonathan Rogers @drjprogers]

Our letter on why meritocratic selection is the best way to choose doctors for training posts is just out in @TheBJPsych.

Lotteries and quotas are bad for both doctors and patients.

https://t.co/czjrWZmFXF

Thanks to Ishaac Awatli & @talia_eilon for collaborating!

[Sameer Jauhar @sameerjauhar]

Privilege to interview John Kane, highlights as folllows https://t.co/0RhBSFZYFR

[Tony Cleare @TCleare]

Published today in Lancet Psychiatry, after 7 years of hard labour... the first long-term head-to-head comparison of two augmentation treatments in treatment resistant depression. Clinical and cost-effectiveness of lithium versus quetiapine augmentat... https://t.co/tF5qUcTkzl

[Robert Howard @ProfRobHoward]

Anyone who conducts clinical trials in the UK will be unsurprised by this. Although we have fantastic colleagues in Trust R&D departments and the RDNs, the NHS is so flattened and clinicians so demoralised, that it has become difficult to do more than data-based research.

[Rob_McCutcheon @rob_mccutcheon]

@ProfRobHoward It isn’t just general NHS issues. Its expanding bureaucracy,a lack of urgency in unis/NHS, & risk aversion causing delays of yrs. Problems haven’t grown from funding issues, but misplaced incentives where its ok if we never get started as long as the proformas completed correctly

[Rob_McCutcheon @rob_mccutcheon]

This is correct. It does of course also apply to quite a lot of related research that takes a slightly different editorial slant.

[Prof James Davies 💭 @JDaviesPhD]

This study should be taken lightly, apart from the biased sample, any benefit experienced when taking SSRIs is likely due to the natural course of one's distress improving over time, other adjustments being made, confounded by the placebo effect & exaggerated by confirmation bias

[Masud Husain @MasudHusain]

Clinical research in the UK is under threat, partly because it takes so long to get a study or trial approved. Here are some of my suggested solutions in this BMJ Opinion piece @NIHR @wellcometrust @UKRI_News
https://t.co/WGUSjJL7qa

[Sameer Jauhar @sameerjauhar]

A fond farewell to @KingsIoPPN @MaudsleyNHS , and giving a lecture Thursday 1600, hybrid https://t.co/4WlepRp9Sg The Good, the Bad and the Ugly. Will be sticking to the evidence-though hope to be entertaining..

[Riccardo De Giorgi @rdegiorgi]

Our new open-access paper “An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders” https://t.co/6F53jRiXPB is on @NatMentHealth